TY - JOUR
T1 - FDG-PET/CT parameters as predictors of outcome in inoperable NSCLC patients
AU - Nappi, Antonio
AU - Gallicchio, Rosj
AU - Simeon, Vittorio
AU - Nardelli, Anna
AU - Pelagalli, Alessandra
AU - Zupa, Angela
AU - Vita, Giulia
AU - Venetucci, Angela
AU - Di Cosola, Michele
AU - Barbato, Francesco
AU - Storto, Giovanni
PY - 2015/12/1
Y1 - 2015/12/1
N2 - Background. We evaluated the prognostic significance of standardized uptake value (SUVmax), metabolic tumour volume (MTV), and total lesion glycolysis (TLG) in [F-18] FDG PET/CT findings in patients with inoperable non-small-cell lung cancer (NSCLC). Patients and methods. One hundred and three patients (mean age, 65.6 ± 16 years) underwent [F-18] FDG PET/CT before the chemotherapy. The SUVmax value, the MTV (cm3; 42% threshold) and the TLG (g) were registered. The patients were followed up to 18 months thereafter (range 12-55 months). Failure to respond without progression, progression and/or disease-related death constituted surrogate end-points. The optimal SUVmax, MTV and TLG cut-off to predict the patients' outcome were estimated. PET/CT results were then related to disease outcome (progression free survival; PFS). Results. The Kaplan-Meier survival analysis for SUVmax showed a significant shorter PFS in patients presenting with lower values as compared to those with higher (p <0.05, log-rank test). MTV and TLG were not suitable for predicting PFS apart from the subset of patients with mediastinal nodal involvement. Conclusions. Despite the availability of new tools for the quantitative assessment of disease activity on PET/CT, the SUVmax rather than MTV and TLG remains the only predictor for PFS in NSCLC patients. MTV holds a value only when concomitant nodal involvement occurs.
AB - Background. We evaluated the prognostic significance of standardized uptake value (SUVmax), metabolic tumour volume (MTV), and total lesion glycolysis (TLG) in [F-18] FDG PET/CT findings in patients with inoperable non-small-cell lung cancer (NSCLC). Patients and methods. One hundred and three patients (mean age, 65.6 ± 16 years) underwent [F-18] FDG PET/CT before the chemotherapy. The SUVmax value, the MTV (cm3; 42% threshold) and the TLG (g) were registered. The patients were followed up to 18 months thereafter (range 12-55 months). Failure to respond without progression, progression and/or disease-related death constituted surrogate end-points. The optimal SUVmax, MTV and TLG cut-off to predict the patients' outcome were estimated. PET/CT results were then related to disease outcome (progression free survival; PFS). Results. The Kaplan-Meier survival analysis for SUVmax showed a significant shorter PFS in patients presenting with lower values as compared to those with higher (p <0.05, log-rank test). MTV and TLG were not suitable for predicting PFS apart from the subset of patients with mediastinal nodal involvement. Conclusions. Despite the availability of new tools for the quantitative assessment of disease activity on PET/CT, the SUVmax rather than MTV and TLG remains the only predictor for PFS in NSCLC patients. MTV holds a value only when concomitant nodal involvement occurs.
KW - glycolytic activity
KW - Non-small-cell lung cancer
KW - quantitative assessment
KW - survival
KW - [F-18] FDG PET/CT
UR - http://www.scopus.com/inward/record.url?scp=84949513270&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84949513270&partnerID=8YFLogxK
U2 - 10.1515/raon-2015-0043
DO - 10.1515/raon-2015-0043
M3 - Article
AN - SCOPUS:84949513270
VL - 49
SP - 320
EP - 326
JO - Radiology and Oncology
JF - Radiology and Oncology
SN - 1318-2099
IS - 4
ER -